^
Association details:
| Biomarker: | IDH1 mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | Rezlidhia (olutasidenib) (IDH1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2888 Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax
Published date:
11/02/2023
Excerpt:
This descriptive analysis suggests that olutasidenib alone or in combination with azacitidine induce complete remissions in patients with mIDH1 AML or MDS that is R/R to VEN, IVO or even HSCT.
Secondary therapy:
azacitidine
Source:
Title:
2888 Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax
Published date:
11/02/2023
Excerpt:
This descriptive analysis suggests that olutasidenib alone or in combination with azacitidine induce complete remissions in patients with mIDH1 AML or MDS that is R/R to VEN, IVO or even HSCT.
